Letairis vs Remodulin
Side-by-side cost comparison based on Medicare Part D data
Letairis
Ambrisentan
Manufactured by Gilead
Remodulin
Treprostinil (SC/IV)
Manufactured by United Therapeutics
Letairis costs 60% less per claim than Remodulin ($8,338.00 vs $20,857.00). A generic version of Letairis is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Letairis | Remodulin |
|---|---|---|
| Avg Cost Per Claim | $8,338.00 | $20,857.00 |
| Total Medicare Spending | $567.0M | $876.0M |
| Total Beneficiaries | 6,800 | 4,800 |
| Total Claims | 68,000 | 42,000 |
| Annual Cost/Patient | $83,382.00 | $182,500.00 |
| Year-over-Year Change | -4.8% | +8.6% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Gilead | United Therapeutics |
| Condition | Pulmonary Hypertension | Pulmonary Hypertension |
| Generic Name | Ambrisentan | Treprostinil (SC/IV) |
Letairis vs Remodulin: What the Data Shows
Letairis (Ambrisentan) and Remodulin (Treprostinil (SC/IV)) are both used to treat pulmonary hypertension. Based on Medicare Part D data, Letairis costs $8,338.00 per claim, which is 60% less than Remodulin at $20,857.00 per claim.
Medicare spent $567.0M on Letairis and $876.0M on Remodulin. In terms of patient reach, Letairis serves more beneficiaries (6,800 vs 4,800).
Year-over-year spending changed -4.8% for Letairis and +8.6% for Remodulin.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Letairis is cheaper at $8,338.00 per claim, compared to $20,857.00 for Remodulin. That makes Letairis about 60% less expensive per claim based on Medicare Part D data.
Yes, both Letairis and Remodulin are used to treat pulmonary hypertension. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Ambrisentan and generic Treprostinil (SC/IV) can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $567.0M on Letairis covering 6,800 beneficiaries, and $876.0M on Remodulin covering 4,800 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.